(NASDAQ: EVAX) Evaxion A's forecast annual revenue growth rate of 160.6% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 56.38%, and it is also forecast to beat the US market's average forecast revenue growth rate of 9.68%.
Evaxion A's revenue in 2025 is $3,344,000.On average, 1 Wall Street analysts forecast EVAX's revenue for 2025 to be $736,370,838, with the lowest EVAX revenue forecast at $736,370,838, and the highest EVAX revenue forecast at $736,370,838. On average, 1 Wall Street analysts forecast EVAX's revenue for 2026 to be $934,840,311, with the lowest EVAX revenue forecast at $934,840,311, and the highest EVAX revenue forecast at $934,840,311.
In 2027, EVAX is forecast to generate $4,754,150,391 in revenue, with the lowest revenue forecast at $4,754,150,391 and the highest revenue forecast at $4,754,150,391.